Extracorporeal shockwave therapy
Extracorporeal shockwave therapy has been studied in 3 papers since 2025: none in people yet, 2 in animals, 1 review. The research so far is in animals. The newest paper, Jul 17, 2025: “Radial Extracorporeal Shockwave Therapy Reduces Subchondral Osteoblast Senescence in Knee Osteoarthritis”.
Part of Bryan Johnson's Blueprint
- 2 independent labs in 1 country
- Funder: National Natural Science Foundation of China
- Animals2
What did studies of Extracorporeal shockwave therapy find?
3Studies of Extracorporeal shockwave therapy measured 3 outcomes; the most studied are cellular senescence (1 study), cartilage integrity damage (1) and bone mass (1).
Cellular senescence
downin rats1
1 study
Cellular senescence
downin rats1
Extracorporeal shockwave therapy decreases cellular senescence in rats.
“These abnormalities, along with damaged cartilage integrity and SCB microarchitecture, were evident in rats with MIA-induced OA but were alleviated by rESWT”
Animalsin MIA-induced knee OAsubchondral bone4 weeksmales
The American journal of sports medicine
Cartilage integrity damage
downin rats1
1 study
Cartilage integrity damage
downin rats1
Extracorporeal shockwave therapy decreases cartilage integrity damage in rats.
“These abnormalities, along with damaged cartilage integrity and SCB microarchitecture, were evident in rats with MIA-induced OA but were alleviated by rESWT”
Animalsin MIA-induced knee OAsubchondral bone4 weeksmales
The American journal of sports medicine
Bone mass
upin rats1
1 study
Bone mass
upin rats1
Extracorporeal shockwave therapy increases bone mass in rats.
“3 bar r-ESW treatment effectively increased bone mass, stimulated new bone formation and decreased osteoclast activity and senescence-associated markers in vivo”
Animalsin an ovariectomy-induced osteoporotic rat model3 bar
Regenerative biomaterials